Login to Your Account



Incyte's JAK Program Scores Again; up to $755M from Lilly

By Jennifer Boggs


Tuesday, December 22, 2009
On the heels of a potential $1 billion oncology collaboration, Incyte Corp.'s JAK program snagged another partner, licensing oral JAK/JAK2 inhibitor INCB28050 to Eli Lilly and Co. in a potential $755 million deal that gives the biotech some big pharma muscle in the crowded rheumatoid arthritis space. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription